Reading this on a mobile device? Try our optimized mobile version here:

November 5, 2012
California voters will soon decide whether to require food labels for GMOs -- but is it scaremongering or progress? Learn more about Proposition 37 and GMOs on BIOtechNOW.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Pioneering gene therapy gains approval in Europe
    The European Commission approved uniQure's Glybera, or alipogene tiparvovec, for the treatment of the exceedingly rare genetic disorder lipoprotein lipase deficiency. The approval makes Glybera the first gene therapy to be cleared in a Western market. UniQure is preparing to apply for regulatory approval in other markets, including the U.S. and Canada. BioWorld Online (free registration) (11/2), Reuters (11/2) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Roche's Zelboraf and Bristol's Yervoy win NICE support
    The U.K. National Institute for Health and Clinical Excellence recommended Roche Holding's Zelboraf, or vemurafenib, and Bristol-Myers Squibb's Yervoy, or ipilimumab, for use by the National Health Service in the treatment of skin cancer. The agency initially decided not to endorse the drugs but reversed its decision after Roche and Bristol agreed to offer the drugs at a discounted price. Reuters (11/2), (India) (11/3) LinkedInFacebookTwitterEmail this Story
  • Activated immune cells protect stem cells
    Israeli researchers have discovered that stem cells are preserved by a subgroup of activated immune cells that also can protect them from chemotherapy and infection. The team also found that prostaglandin treatment can boost the amount of stem cells and enhance cell quality, a development that may help improve treatments for leukemia. The Jewish Press (10/31) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Advaxis raises $11.4M for immunotherapy program
    Advaxis, which develops immunotherapies for cancer, secured $10 million in equity funding from Magna Group Capital Management and $1.4 million in convertible notes and warrants. Proceeds will go toward the company's immunotherapy program. (11/1) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • Industry reconfirms commitment after BP's project cancellation
    Abengoa, ZeaChem, Novozymes North America and DuPont Industrial Biosciences reaffirmed their commitment to develop advanced biofuels after BP's announcement last week that it was backing away from its cellulosic ethanol project in Florida. "America needs a mix of domestically made renewable fuels to keep fuel affordable for U.S. drivers, improve our security and protect the environment -- and that's why continued investment in advanced biofuels makes sense," said Novozymes North America President Adam Monroe. BP said it will find ways to commercialize its cellulosic ethanol technology while keeping its operations in Brazil and the U.K. (11/2) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Whoever is winning at the moment will always seem to be invincible."
--George Orwell,
British novelist and journalist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information